Introduction
Epilepsy, antiepileptic drugs, and the reproductive system have complex interactions. Fertility is lower in both men and women with epilepsy than in the general population. [1] [2] [3] Moreover, reproductive Summary Epilepsy, antiepileptic drugs (AEDs), and the reproductive system have complex interactions. Fertility is lower in both men and women with epilepsy than in the general population. Moreover, reproductive endocrine disorders are more common among patients with epilepsy than among the population in general. These disorders have been attributed both to epilepsy itself and to AEDs. The use of the liver enzyme inducing AEDs phenobarbital, phenytoin and carbamazepine increases serum sex hormone binding globulin (SHBG) concentrations in both men and women with epilepsy. Over time the increase in serum SHBG levels leads to diminished bioactivity of testosterone and estradiol, which may result in diminished potency in men and menstrual disorders in some women, and, thus, to reduced fertility.
Valproate (VPA) medication may have effects on serum androgen concentrations and it reduces serum follicle stimulating hormone levels in men with epilepsy. However, the clinical significance of the VPA related reproductive endocrine changes in men is unknown. On the other hand, in women the use of VPA is associated with a frequent occurrence of reproductive endocrine disorders characterized by polycystic changes in the ovaries, high serum testosterone concentrations (hyperandrogenism) and menstrual disorders. Young women with epilepsy seem to be especially vulnerable to the effects of VPA on serum androgen levels.
The endocrine effects of the new AEDs have not been widely studied. However, it seems they may offer an alternative if reproductive endocrine problems emerge during treatment with the older antiepileptic drugs. On the other hand, it seems that in many cases the reproductive endocrine effects of the AEDs are reversible, if the medication is discontinued. # 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
endocrine disorders are more common among patients with epilepsy than among the population in general. [4] [5] [6] These disorders have been attributed both to epilepsy itself and to antiepileptic drugs (AEDs). The potential effects of epilepsy on reproductive endocrine function are reviewed in detail elsewhere in this journal. However, it is evident that AEDs may also alter endocrine function in both men and women with epilepsy and that this alteration may lead to clinically significant reproductive endocrine 
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High SHBG levels associated with diminished potency, 5-year prospective data* CBZ* 11 disorders in certain cases. 7 This review focuses on the reproductive endocrine effects of AEDs.
Reproductive endocrine effects of antiepileptic drugs in men
It is well known that AEDs may have undesirable effects on male sexual function. It was already known in the 1850s, when bromides were introduced as a treatment for epilepsy, that these salts produced impotence. 7 Later, a randomized drug trial showed the development of impotence or decreased libido in 11-22% of patients after starting monotherapy with carbamazepine (CBZ), phenytoin (PHT), phenobarbital or primidone. However, no endocrine data was obtained in that study. 7 The first studies reporting reproductive endocrine abnormalities in men taking AEDs and associating them in some cases with sexual dysfunction were published in the 1970s and 1980s. An increase in serum sex hormone binding globulin (SHBG) levels and a consequent decrease in bioactive androgens was a consistent finding. SHBG is synthesized in the liver, and it binds and regulates the bioactivity of both testosterone and estradiol in the circulation. While serum total testosterone levels were elevated or normal, low levels of serum bioactive androgens seemed to be associated with diminished sexual functions. However, in most of these first studies, the patients were on polytherapy, which in nearly all cases included different liver enzyme inducing AEDs (EIAEDs). The specific effects of particular AEDs on reproductive endocrine function were therefore difficult to differentiate. Studies on reproductive endocrine effects of single AEDs in men with epilepsy will be reviewed in the following. These studies are summarized in Table 1 .
Phenobarbital, phenytoin, carbamazepine
After the early studies in men with epilepsy on polytherapy with EIAEDs additional studies have shown that all these drugs taken as monotherapy are also associated with high serum SHBG levels and a consequent diminution of free androgens available for the tissues, which may be associated with diminished sexual function in men. Elevated serum estradiol levels have also been reported in men on PHT, and high estradiol levels were found to be associated with sexual dysfunction in some men. 7 The reproductive endocrine effects of CBZ in men with epilepsy appear to be similar to those observed during PHT medication, except that CBZ has not been reported to be associated with elevated serum total testosterone or estradiol concentrations. Many cross-sectional and prospective studies have reported that an increase in serum SHBG concentrations results in decrease in the levels of bioactive free androgens (free androgen index, FAI). 7 Prospective studies have shown that the use of CBZ is associated with a progressive increase in serum levels of SHBG resulting in low free androgen index (FAI) ratios reflecting decreased serum levels of free, bioactive testosterone in male patients. 8 This progressive change appears to result in sexual dysfunction in some men with epilepsy after long-term CBZ treatment. Low serum DHEAS levels have also been reported in men on PHT or CBZ. DHEAS is a weak androgen secreted by the adrenal cortex, and the clinical significance of decreased serum DHEAS concentrations is unknown. It has been suggested that the metabolism of hormones and synthesis of hormone binding globulins is increased during medication with EIAEDs due to liver enzyme induction. No consistent abnormalities have been found in the basal or stimulated serum PRL or gonadotropin levels in men taking phenobarbital, PHT or CBZ for epilepsy. 7 It has been suggested that PHT may reduce sperm motility. Furthermore, in one study, PHT medication was associated with reduced semen volume, spermatozoa concentration and possibly sperm count. CBZ has also been suggested to reduce sperm motility. This was first observed in an in vitro study, and, therefore was a direct effect of CBZ on sperm cells. 7 Just recently, two clinical studies in men with epilepsy have shown that CBZ is associated with reduced sperm motility and increased frequency of morphologically abnormal sperm.
9,10
Valproate Valproate (VPA) is not an EIAED. However, studies suggest that in addition to reducing serum gonadotropin levels, VPA also increases serum androstendione concentrations in men with epilepsy. The mechanism by which VPA alters reproductive endocrine function in men with epilepsy is unknown. VPA modifies GABA-ergic neurotransmission and could alter the secretion of gonadotropins. On the other hand, a direct effect of VPA on testicular androgen synthesis is possible. 7 Cases of infertility have been reported in male subjects taking VPA for epilepsy. An in vitro study suggested that VPA has direct effects on sperm motility. 7 Two recent clinical studies also showed that VPA may reduce the sperm motility and increase the frequency of morphologically abnormal sperm, and be associated with small testicular size in men with epilepsy.
Oxcarbazepine Oxcarbazepine (OXC) is a novel AED that structurally closely resembles CBZ. However, it has a different metabolic pathway in the liver: instead of oxidation it is mainly metabolized by reduction and it does not appear to induce the oxidative P450 enzyme system. Earlier studies have shown that CBZ induced liver enzyme induction and associated changes in endocrine and metabolic function become normal after CBZ is replaced with OXC in men with epilepsy. However, there is evidence that OXC may also induce liver enzymes when given in higher doses, and one study reported that it may have effects on the bioactivity of serum steroids by increasing serum testosterone and SHBG concentrations when taken in high doses in men with epilepsy. 7 Another recent clinical study suggested that OXC may be associated with increased frequency of morphologically abnormal sperm in men with epilepsy. 9 
Lamotrigine
In a comparison of sexual function and reproductive hormone levels among men with localization related epilepsy on lamotrigine, enzyme inducing AEDs, and normal controls, sexual function scores, bioactive testosterone levels, bioactive testosterone/bioactive estradiol and bioactive testosterone/LH were significantly lower in the patient group on liver enzyme inducing AEDs than in men treated with lamotrigine (LTG) or the control subjects. SHBG was also significantly higher in the induced group than in all other groups (Table 1) . 7 
Other new antiepileptic drugs
The hormonal effects of the other new AEDs (felbamate, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin) have not been studied in men with epilepsy.
Reproductive endocrine effects of AEDs in male subjects with epilepsy during pubertal development A recently published study evaluated reproductive endocrine function in boys and young men taking CBZ, LTG, OXC, or VPA as monotherapy for epilepsy. 11 Patients taking VPA had high serum androstenedione levels at all pubertal stages. In prepuberty, their serum androstenedione values were already approximately fivefold compared with the values of the control subjects, and they were elevated in 64% of the VPA treated patients compared with none of the other patients.
Consistent with what has previously been reported in adult male subjects with epilepsy serum SHBG levels were increased and serum DHEAS concentrations decreased in pubertal patients taking CBZ. However, the serum levels of these hormones were not affected in prepuberty. LTG and OXC were not associated with changes in serum sex hormone levels in boys and young men with epilepsy.
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Reproductive endocrine effects of antiepileptic drugs in women A high number of irregular menstrual cycles in women with epilepsy were reported in the mid 1950s by Laidlaw. Thereafter, reproductive endocrine disorders were suggested to be associated with epilepsy itself rather than with the medication. However, in the late 1970s and 1980s serum SHBG levels were reported to be elevated in women taking EIAEDs for epilepsy, and Margraf and Dreifuss were the first to report amenorrhea following initiation of therapy with VPA, indicating a drug-induced effect. 7 Studies on the reproductive endocrine effects of AEDs in women with epilepsy will be reviewed in the following. The studies are summarized in Tables 2 and 3 .
Phenobarbital, phenytoin, carbamazepine
In 1977 Victor et al. showed that PHT medication was associated with elevated serum SHBG concentrations in women with epilepsy, and this finding was later confirmed. Low DHEAS levels have also been reported in women on PHT. The findings of many cross-sectional and prospective studies on the reproductive endocrine effects of CBZ in women with epilepsy are fairly consistent in reporting increased serum SHBG levels. Similarly to men the increase in serum levels of SHBG is progressive in women taking CBZ for epilepsy. The increase in SHBG serum concentrations results in a decreased amount of bioactive estradiol, which may be associated with menstrual disorders in some women after long-term treatment. The increase in serum SHBG levels also results in a reduction of bioactive testosterone (FAI). This effect of CBZ may theoretically be advantageous in women with hyperandrogenism. Low serum DHEAS levels have also been reported in women on CBZ. However, the clinical significance of the decreased serum concentrations of this weak androgen is unknown. No consistent abnormalities in basal or stimulated serum gonadotropin or PRL levels have been reported in women taking PHT or CBZ for epilepsy.
Valproate
Reproductive endocrine effects of VPA in women with epilepsy have not been systematically studied until the early 1990s. The first report suggesting a high incidence of menstrual disorders, linked to obesity, hyperandrogenism and polycystic ovaries, in women taking VPA for epilepsy was published in 1993. 6 Thereafter, many studies on reproductive endocrine effects of AEDs in women with epilepsy have been published. 7 The results of the studies are summarized in Tables 2 and 3. A randomized, openlabel prospective study comparing the reproductive endocrine effects of VPA and LTG was recently completed and the results of that study will be discussed later in this review.
The cross-sectional study from 1993 is the only study in this field that included a large hospitalbased patient population. Altogether 238 women participated in the study. 6 The major finding in the study was that menstrual disorders were common among women taking VPA monotherapy for epilepsy (45%), and that they were frequently associated with polycystic ovaries (PCO) and/or hyperandrogenism, which were seen in 9/10 (90%) of the women on VPA monotherapy who had menstrual disorders. PCO and hyperandrogenism were especially common, if VPA medication was started before the age of 20. Moreover, the serum mean androgen levels were increased in women on VPA. 6 Later, similar findings were obtained from a three-centre study conducted in three European Disorders of reproduction in patients with epilepsy 115 countries (Finland, Norway, Netherlands): menstrual disorders were reported by 59% of women on VPA as compared to 12% of CBZ-treated women and 15% of control women. Hyperandrogenism and/ or PCO were detected in 70% of VPA-treated women as compared to 20% in the CBZ-treated women and 19% among the control women. Moreover, a shortterm (3 months) prospective study in newly diagnosed women starting treatment with VPA suggested that an increase in serum testosterone and androstendione levels can be seen in approximately half of the women within 3 months after starting VPA. 7 Changes in serum androgen levels have been detected already before and during pubertal development in young girls taking VPA for epilepsy. 12 The mean serum testosterone levels and FAI were high in all pubertal phases in girls on VPA. Moreover, elevated serum testosterone levels were found in 38% of the prepubertal, 36% of the pubertal, and 57% of the postpubertal girls, whereas hyperandrogenism was seen in only 8% of the pubertal and in none of the pre-or post-pubertal control girls. 12 A 5-year follow-up of these girls was just recently reported. 13 Sixty percent of the girls/women who were on VPA during the follow-up study had polycystic ovary syndrome (PCOS) as compared to 25% of girls/ women taking other AEDs, 5.5% of girls whose medication had been discontinued, and 8.3% of control subjects. Interestingly, out of the 15 girls who had hyperandrogenism while on VPA during pubertal development, 5/7 (71.4%) of the girls who still continued VPA at the time of follow-up had PCOS, as compared to 1/4 (25%) among girls/ women who had been switched to other medication and 0/4 among girls whose medication had been discontinued.
Two studies by Murialdo et al. have also reported high prevalence of menstrual disorders and hyperandrogenic anovulation in VPA-treated women with epilepsy. 7 However, the study by Bauer et al. did not show any differences between CBZ-and VPA-treated women with epilepsy with regard to reproductive endocrine parameters, but the interpretation of the results of this study is difficult, because the age of the patients, the duration of medication, and seizure frequency in the different treatment groups were not given. 7 Four other studies have also addressed the issue of reproductive endocrine function in women with epilepsy. Luef et al. reported similar frequency of menstrual disorders and PCO in women taking either CBZ or VPA for epilepsy. Morrell et al. studied predictors of ovulatory failure in 94 women with epilepsy. Of women using VPA currently or within the preceding 3 years, 38.1% had experienced at least one anovulatory cycle in contrast to 10.7% of women not using VPA within the preceding 3 years. Moreover, women with idiopathic generalized epilepsy receiving VPA were at highest risk for anovulatory cycles, polycystic-appearing ovaries, elevated body mass index, and hyperandrogenism. Another recent study by Morrell et al. reported higher serum testosterone levels in women taking VPA for epilepsy than in women taking LTG. 7 Finally, the recent study by Betts et al. found a 30% prevalence of PCOS in women ever treated with VPA only as compared to 6% in women ever treated with either CBZ or LTG only or to 14% among healthy control women. 14 It has been suggested that obesity and associated hyperinsulinemia could be implicated in the development of PCO and hyperandrogenism in women taking VPA. However, PCO and hyperandrogenism were also found in many lean VPA-treated women without hyperinsulinemia, and hyperandrogenism in prepubertal, pubertal and postpubertal girls taking VPA for epilepsy was not associated with hyperinsulinemia. 7, 12 Hence, obesity and elevated serum insulin levels do not appear to be the main factors initiating the process leading to hyperandrogenism and the development of PCO in VPA-treated women. However, it seems that obesity and related hyperinsulinemia may exacerbate the VPA-related reproductive endocrine disorders in women with epilepsy. It seems likely that VPA has a direct effect on ovarian androgen production, or as an enzyme inhibitor, it may inhibit the metabolism of sex steroids and thereby lead to increased serum androgen levels. 7 A recent prospective, randomized, open-label, multicentre 12-month study evaluated the development of components of PCOS and PCOS in 13-40-year-old women with epilepsy initiating VPA or LTG. 15 A post hoc analysis was conducted in women >2 years post-menarche (177 LTG, 186 VPA) to exclude the confounding effect of puberty.
Interestingly, in this study the prevalence of PCO was $45% at baseline supporting the theory that epilepsy itself may alter reproductive endocrine milieu in women with epilepsy. The LH/FSH ratio was elevated in women with PCO, and the PCO status at baseline predicted development of ovulatory dysfunction during VPA treatment further emphasizing the relevance of the PCO findings in the untreated women with epilepsy. 16 More women in the VPA group than the LTG group developed hyperandrogenism or ovulatory dysfunction in both the prospective analysis (54% VPA, 38% LTG; p = 0.010) and the post hoc analysis (36% VPA, 23% LTG; p = 0.007). Development of hyperandrogenism or ovulatory dysfunction was more frequent with VPA than LTG among those initiating treatment at age <26 years (44% VPA, 23% LTG, p = 0.002) but was similarly frequent between groups if treatment was started at age !26 years (24% valproate, 22% lamotrigine). The first year of VPA treatment was associated with a significant increase in serum testosterone concentrations in young women with epilepsy, and this increase was especially prominent in women who were younger than 20 years of age when the medication was started. 15 The impact of age on the development of valproate-related hyperandrogenism in women with epilepsy
The likelihood of developing components of PCOS with VPA treatment appears to depend on the age at which VPA is introduced. In the prospective study comparing the endocrine effects of VPA and LTG, women with epilepsy beginning treatment with VPA at age <26 years were at highest risk for developing components of PCOS whereas those women beginning treatment with VPA at age !26 years had no higher risk than women with epilepsy receiving LTG. In addition, the women who started VPA at the younger age had a prominent increase in serum testosterone levels. This observation is consistent with the possibility that a direct effect of VPA on ovarian androgen secretion may lead to development of components of PCOS in women with epilepsy and that the younger ovary may be more vulnerable to this effect. 15 Other studies have made similar observations regarding the particular vulnerability of younger women. In one cross-sectional investigation, more than 60% of women with epilepsy receiving VPA before age 20 had polycystic-appearing ovaries as determined by transvaginal ovarian ultrasound in contrast to 27% of women with epilepsy receiving other antiepileptic drugs. 6 In another cross-sectional study, elevation in serum testosterone levels was found only in women who had started treatment with valproate prior to age 25. 14 
Oxcarbazepine
There are not much data on the reproductive endocrine effects of OXC in women with epilepsy. No reproductive endocrine abnormalities were found during OXC therapy in girls during pubertal development. 12 Moreover, in the follow-up report of these girls, no OXC-related endocrine abnormalities were found. 13 In a recently published study CBZ and OXC had different effects on reproductive endocrine function in women with epilepsy. Although both drugs were associated with low serum T concentrations and low FAI, only OXC was associated with a high frequency of elevated levels of A and DHEAS and with an increased prevalence of PCO. 17 
Lamotrigine
Replacement of VPA with LTG resulted in normalization of endocrine function during 1-year followup in women with a previously identified reproductive endocrine disorder likely related to VPA medication. This suggests that LTG therapy is not associated with changes in body weight, or in endocrine and metabolic functions in women with epilepsy. Consistent with these data, Morrell et al. reported that women taking LTG for epilepsy had lower serum testosterone concentrations than women taking VPA. 7 Moreover, Betts et al. found a low prevalence of PCOS (6%) among women taking either LTG or CBZ for epilepsy.
14 However, these women were presented as one group, and the number of women on either drug, or the individual results for either drug were not given.
Other new antiepileptic drugs
The reproductive endocrine effects of other new AEDs (e.g. felbamate, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, vigabatrin) have not been systematically studied in women with epilepsy.
Reversibility of the reproductive endocrine effects of antiepileptic drugs after discontinuation of the medication Several studies have suggested that the reproductive endocrine effects of AEDs may be reversible, if the medication is discontinued. CBZ induced liver enzyme induction and associated changes in endocrine and metabolic function became normal after CBZ was replaced with OXC in men with epilepsy. In another prospective study replacement of VPA with LTG resulted in normalization of endocrine function during a 1-year follow-up in 12 women with a previously identified endocrine disorder (PCO or hyperandrogenism or both) likely to be related to VPA medication. Serum insulin and testosterone levels returned to normal in 2 months after VPA was discontinued, and the levels remained normal thereafter.
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A 5-year follow-up study in young female subjects with epilepsy was recently reported. 13 Sixty percent of the girls/women who were on VPA during the follow-up study had PCOS as compared to 5.5% of girls whose medication had been discontinued. Interestingly, out of the 15 girls who had hyperandrogenism while on VPA during pubertal development, 5/7 (71.4%) of the girls who still continued VPA at the time of follow-up had PCOS compared to 0/4 among girls whose medication had been discontinued. 13 Another recent study that investigated the reversibility of the effects of AEDs on reproductive endocrine function after withdrawal of AEDs also showed that withdrawal of CBZ led to significant increases in serum testosterone concentrations and FAI in both men and women suggesting that at last some of the CBZ-associated endocrine changes may be reversible after the medication is discontinued. 18 
Summary and conclusions
It is well established that most of the old AEDs have effects on reproductive function in patients with epilepsy. It is probable that epilepsy itself may modulate the regulation of reproductive endocrine function in men and women with epilepsy and that epilepsy may modify the effects that AEDs have on reproductive function. The underlying mechanisms, clinical significance and incidence of the AEDrelated reproductive changes differ between various AEDs. However, it is well established that AEDs with liver enzyme inducing properties decrease the serum concentrations of bioactive sex steroids, whereas VPA increases the serum concentrations of androgens.
It is important to acknowledge that the reproductive effects of AEDs may be different depending on the age. Young women with epilepsy seem to be especially vulnerable to the effects of VPA on ovarian function.
The endocrine effects of the new antiepileptic drugs have not been widely studied. However, it seems they may offer an alternative if reproductive endocrine problems emerge during treatment with the older AEDs. It is encouraging to note that most of the reproductive effects of the AEDs appear to be reversible, if the medication is discontinued before adulthood.
